Objective:To study the correlation between ProMisE molecular classification of endometrial cancer and lymph node metastasis and clinical features.Methods:1,056 endometrial cancer patients were selected as the research subjects.The ProMisE molecular typing results,lymph node metastasis,and indicators of clinical characteristics were analyzed.The correla-tion of patient ProMisE molecular subtyping with lymph node metastasis and clinical characteristics was analyzed.Results:A-mong the 1,056 patients,the ProMisE molecular typing as MMRD totaled 384 cases,accounting for 36.36％.In total,72 cases were POLE EDM subtype,accounting for 6.82％,p53abn was total of 96 cases,accounting for 9.09％.The p53wt totaled 504 cases,accounting for 47.73％.The proportion of p53wt was higher than that of POLE EDM and p53abn(P＜0.05).The posi-tive ProMisE molecular classification of endometrial cancer was positively associated with lymph node metastasis,clinical sta-ges,CA1 2 5 and CA199(r=0.572,0.641,0.778,0.804,P=0.002,0.002,0.002,0.001),and showed no obvious correlation with age,WBC and ANC(r=0.119,0.251,0.187,P=0.104,0.573,0.311).Conclusion:The ProMisE molecular classification of endometrial cancer is closely associated with lymph node metastasis,clinical stages,CA125 and CA199,and has no obvious association with other clinical features,which deserves clinical attention.